Panasonic: Verification of inhibitory effect of nanoe™ X, technology with the benefits of hydroxyl radicals on novel coronavirus (SARS-CoV-2)
26.10.2020 14:00:00 EET | Business Wire | Press release
Panasonic today announced that, in collaboration with the global contract research organization Texcell*1, Texcell has verified the inhibitory effect of the nanoe™ X, technology with the benefits of hydroxyl radicals on the novel coronavirus (SARS-CoV-2).
nanoe™ X, the original ionizer to generate “nano-sized atomized water particles” is developed by Panasonic. It is an electrostatic atomization technology, that collects invisible moisture in the air and applies high voltage to it to produce “hydroxyl radicals contained in water”. The decisive factor is the existence of hydroxyl radicals inside nanoe™ X. Hydroxyl radicals are characterized by being strongly oxidative and highly reactive.
Panasonic has been conducting research on this technology since 1997, and has verified its effectiveness in a variety of areas, including inhibiting certain pathogenic microorganism (bacteria, fungi, and viruses) and allergens, breaking down PM 2.5 components that have adverse effects on the human body*2.
In 2012, Panasonic conducted a virus clearance test with a third-party organization and confirmed the effectiveness of each of the four categories in terms of biological characteristics. Based on this result, Panasonic announced that "hydroxyl radicals contained in water" technology could be expected to have an inhibitory effect on new viruses*3.
The novel coronavirus (SARS-CoV-2) of the current global pandemic is one such new type of virus and testing with Texcell has now confirmed that the nanoe™ X does have an inhibitory effect on this virus. This testing was carried out in a closed laboratory environment and was not designed to assess its efficacy in uncontrolled living spaces.
Panasonic will continue to pursue the potential of nanoe™ X technology to address possible risks associated with air pollution such as new pathogenic microorganisms, with the aim of creating cleaner environments for people around the world.
For reference :
Testing of inhibitory effect of nanoe™ X on the novel coronavirus (SARS-CoV-2)
・ Overview
A comparative verification was conducted in a 45L test space containing the novel coronavirus (SARS-CoV-2) with and without exposure to nanoe™ X.
・ Results
Over 99.99% of novel coronavirus (SARS-CoV-2) activity was inhibited within 2 hours.
Note: This verification was designed to generate basic research data on the effects of nanoe™ X on the novel coronavirus in laboratory conditions different from those found in living spaces. It was not designed to evaluate product performance.
・ Methodology and data
Organisation :Texcell
Subject :Novel coronavirus (SARS-CoV-2)
Device :nanoe™ X device
Method:
- nanoeTM X device is installed at 15cm from the floor in the 45L test space.
- A piece of gauze saturated SARS-CoV-2 virus solution was placed in a petri dish and exposed to nanoeTM X for a predetermined time.
- The virus infectious titer was measured and used to calculate the inhibition rate.
・ Results data
|
Test subject |
Inhibition rate* |
Capacity |
Hours |
|
SARS-CoV-2 |
99.99% |
45L |
2 hours |
Notes:
*1: Texcell is a global contract research organization that specializes in viral testings, viral clearance, immunoprofiling and R&D or GMP cell banking, for your R&D, GClP, GLP and GMP projects.
With more than 30 years of experience and roots within the Pasteur Institute in Paris, Texcell has a long recognized expertise in viral testing with a broad range of protocols for the detection of adventitious agents.
Texcell is the first spin-off of the Pasteur institute of Paris created in 1997.
*2: Main releases on verification cases
- May 12, 2009:Positive effects of charged water particles on viruses, bacteria, and agricultural chemicals have been verified.
- October 20, 2009: The new influenza virus inhibition effect of charged water particles has been verified.
- February 20, 2012:Suppression effect of charged water particles on pet-related allergens, bacteria, fungi, and viruses have been verified.
- January 16, 2014:Nano-sized electrostatic atomized water particles effectively breaks down PM2.5 components and inhibits growth of fungi attached to Yellow Sand.
*3: January 26, 2012: Virus suppression effect of charged water particles has been verified by the virus clearance test. Co-verified with Charles River Biopharmaceutical Services GmbH, a German testing organization.
About Panasonic
Panasonic is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 528 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers.
https://www.panasonic.com/global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005047/en/
Contact information
Media Contact:
Tanya.houston@wildwoodpr.com
Tel: +44 (0) 1293 851115
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
